Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

por Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.
Publicado 2023

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM...

por Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A
Publicado 2022

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

por Bobin, A., Manier, S., De Keizer, J., Karlin, L., Perrot, A., Hulin, C., Caillot, D., Mariette, C., Lenain, P., Richez, V., Tiab, M., Touzeau, C., Jaccard, A., Decaux, O., Araujo, C., Belhadj, K., Benboubker, L., Déal, C., Macro, M., Vincent, L., Arnulf, B., Bareau, B., Braun, T., Calmettes, C., mamoun, D., Zerazhi, H., Demarquette, H., Feugier, P., Fohrer-sonntag, C., Godet, S., Petillon, M.-O., Avet-Loiseau, H., Leleu, X.
Publicado 2022